Adherence
Off-label use of GLP-1 agonists by healthy athletes for aesthetic or performance purposes raises ethical, legal, and safety concerns, including potential classification as doping and inequality in sports access.
Using GLP-1 agonists off-label for aesthetic or performance reasons is not approved and carries ethical and legal risks. It may be viewed as doping and creates inequality in sports. Athletes should consult regulatory bodies and prioritize approved medical indications over off-label use for performance enhancement.
The off-label utilization of these medications inevitably carries inherent risks and raises significant ethical considerations... Additionally, ethical concerns arise regarding the potential classification of GLP-1 agonists as a form of doping... Another issue is the inequality in access to these medications.
Why this rating
Based on regulatory status, ethical analysis, and societal trends described in the review.
Source
NEXT-GENERATION GLP-1 PHARMACOTHERAPY: ADVANCES IN OBESITY TREATMENT WITH CONSIDERATIONS FOR PHYSICAL PERFORMANCE AND POPULATION HEALTH
Bartosz Skorupski et al. · International Journal of Innovative Technologies in Social Science · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →